Bedinvetmab (Librela®), a novel treatment for canine osteoarthritis (OA), has shown significant effectiveness across five European countries. In a study with over 1,900 patient records, veterinarians reported a high satisfaction rate of 8.0 out of 10.0, with fewer than 1% discontinuing use due to dissatisfaction. Bedinvetmab reduced the need for multiple pharmacological treatments, with the proportion of dogs requiring additional medication for OA pain dropping from 47% to 31%. This new therapy offers hope for better pain management and improved quality of life for dogs suffering from OA.

A recent European survey conducted among ulcerative colitis patients and physicians highlights the importance of medication formulation on treatment adherence. The majority of patients preferred tablet formulations over granules, with 58% choosing tablets due to their ease of use and convenience. Physicians also favored tablets, believing that patients were more adherent and experienced better symptom relief compared to granules. However, both patients and physicians agreed that reducing the pill burden and simplifying dosing regimens would significantly improve adherence, particularly for those struggling with multiple daily doses.

Many of our clients in the pharmaceutical industry utilize the marketing studies we conduct to enhance their market insights and communicate effectively with stakeholders. Our studies provide valuable quantitative and qualitative data, enabling pharmaceutical companies to understand current trends, emerging treatments, and industry dynamics. By publishing insights from these studies, clients strengthen their position as opinion leaders, address patient and healthcare professional needs, and bolster their scientific credibility. These publications not only showcase their market leadership but also help differentiate them in a highly competitive industry.